Compliance Program Design And Monitoring

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Private Equity Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated across a multi-product private equity platform and required support with Compliance Program Design And Monitoring in the context of Private Equity. Stakeholders included Mega/Large-Cap Private Equity Buyout Firms executing carve-outs and public-to-privates at pace, Mid-Market & Lower Mid-Market Private Equity Sponsors formalizing first-institutional compliance functions, Growth Equity Investors (Private Equity) scaling with lean teams, Private Equity Operating Partners & Value Creation Teams interacting with MNPI across portfolio boards, and PE-Owned Portfolio Companies subject to sponsor oversight and information-sharing protocols. The diagnostic we conducted surfaced control gaps that raised deficiency and enforcement risk under SEC and FCA supervision and created friction with investors, lenders, and counterparties:

• Program architecture fragmented and reactive
  • Policies existed as static documents without a living compliance risk assessment (CRA), control inventory, or testing calendar. Responsibilities across Legal, Compliance, Finance, IR/Marketing, and Deal Teams overlapped, and issue remediation lacked clear owners and deadlines.
• Regulatory coverage incomplete or inconsistently operationalized
  • SEC Advisers Act requirements (Marketing Rule 206(4)-1, Books & Records Rule 204-2, Code of Ethics Rule 204A-1, Custody Rule 206(4)-2, Pay-to-Play Rule 206(4)-5, Form ADV/Form PF) and FCA regimes (SYSC, COBS, MAR, SMCR, UK AIFMD Annex IV) were addressed on paper but not embedded in workflows or systems; surveillance and evidencing were ad hoc.
• Marketing Rule and performance advertising risk
  • Performance claims, hypothetical performance, and case studies were marketed without centralized substantiation, fair and balanced presentation, or jurisdictional variants; approval workflows were email-based, increasing greenwashing and marketing rule exposure.
• Conflicts of interest and allocation policies not tested
  • Expense allocations (fund vs. management company vs. co-invest), co-invest and deal allocation, cross trades/principal transactions, continuation vehicles, and preferential treatment/side letters were governed by policy but not subjected to forensic testing or MFN trees.
• MNPI, information barrier, and board seat risks
  • Deal teams and Operating Partners held portfolio board seats; controls for MNPI intake, wall crossings, personal trading pre-clearance for access persons, and restricted lists were manual; diligence with public-company counterparties lacked standardized logs.
• Cybersecurity, data privacy, and BCP controls uneven
  • Cyber policies (incident response, DLP, access management), privacy (GDPR/UK GDPR) and vendor risk oversight varied by region; tabletop testing and evidence of control operation were limited; business continuity/disaster recovery testing cadence was irregular.
• Surveillance and testing lacked a calendar and metrics
  • No annual testing plan or risk-based surveillance program existed for fees/expenses, valuation governance, political contributions, gifts & entertainment, outside business activities (OBAs), best execution for liquid strategies, or sanctions/AML screening (where applicable); KRIs and issue dashboards were not maintained.
• Regulatory filings and disclosures misaligned
  • Form ADV/Part 2A/2B updates, Form PF frequency thresholds, Form D/blue sky, AIFMD Annex IV, and FCA notifications were not centrally tracked; LP reports contained language not reconciled to regulatory disclosures; Marketing Rule recordkeeping was incomplete.
• Training and culture program not role-based
  • Annual training was check-the-box; modules were not tailored to deal teams, IR/Marketing, Operating Partners, or portfolio directors; no certification workflow tied to high-risk activities or SMCR conduct rules where applicable.
• Underperforming KPIs
  • Exam deficiency letters required multiple remediation rounds; compliance approval SLAs missed ahead of capital formation milestones; expense allocation and valuation exceptions repeated; Marketing Rule exceptions increased; documentation for MNPI events and personal trading pre-clearance was inconsistent; board and LP Q&A cycles were extended due to evidencing gaps.

2) Project Objective

The primary objective focused on designing and operationalizing an SEC/FCA-compliant compliance program—policies, risk assessment, testing calendar, surveillance, and training—to strengthen the control environment and reduce deficiency and enforcement risk while enabling faster, compliant execution across deals, fundraising, and portfolio oversight.

Secondary objectives included:

• Standing up a living compliance risk assessment (CRA) tied to business model changes, with a control inventory and risk/control ownership.
• Implementing a risk-based annual testing plan and surveillance program covering Marketing Rule, fees & expenses, allocations, MNPI/information barriers, personal trading, political contributions, valuation, cyber/privacy, and BCP.
• Embedding Marketing Rule workflows with centralized substantiation repositories, jurisdictional variants, and recordkeeping aligned to Rule 204-2.
• Operationalizing conflicts governance (co-invest and deal allocation, continuation vehicles, side letter/MFN, cross/principal transactions) with forensic testing and exception logs.
• Codifying MNPI and board seat protocols (wall crossing, restricted lists, calendar controls, diligence logs, personal trading pre-clearance) with DLP/monitoring.
• Aligning SEC/FCA filings and AIFMD/Annex IV reporting with a regulatory calendar, workflow, and evidence retention.
• Deploying role-based training and SMCR/Conduct Rules (where FCA), with certifications linked to high-risk activities and onboarding.
• Standing up governance (Compliance Committee, issue/risk dashboards, KRIs, and remediation SLAs) integrated with the operating cadence and board reporting.

3) Methodology and Approach

Workstream 1: Compliance Risk Assessment (CRA), Control Inventory, and Governance

We established the foundation for a risk-based, auditable program.

• Activities we conducted:
  • Completed a CRA mapping inherent/residual risk across domains: Marketing Rule and advertising, conflicts/fees & expenses, MNPI/information barriers, personal trading/Code of Ethics, AML/sanctions (as applicable), cybersecurity/privacy, valuation governance, pay-to-play/political contributions, gifts & entertainment/OBAs, outsourcing/vendor risk, and regulatory reporting.
  • Built a control inventory linking each risk to policies, procedures, owners, frequency, evidence, and testing steps; prioritized by likelihood/impact and regulatory focus (SEC Division of Examinations priorities, FCA thematic reviews).
  • Stood up governance: Compliance Committee charter, meeting cadence, issue and exception registers, KRI dashboards, and escalation thresholds; defined interfaces with Legal, Finance, IR, IT/Cyber, and Deal Teams.
• Tools/frameworks used: CRA heat map, control inventory, KRI dashboard, Compliance Committee charter, issue/exception registers, remediation tracker.
• Stakeholders involved: CCO, General Counsel, CFO/Controller, Head of IR/Marketing, CIO/Deal Leaders, CISO/IT, Operating Partners.

Workstream 2: Policy Suite Refresh and Procedure Operationalization

We updated policy design and embedded procedures into daily workflows and systems.

• Activities we conducted:
  • Refreshed core policies: Code of Ethics (Rule 204A-1), Marketing and Communications (Rule 206(4)-1), Books & Records (Rule 204-2), Custody (Rule 206(4)-2), Political Contributions (Rule 206(4)-5), Gifts & Entertainment/OBAs, MNPI/Insider Trading and Information Barriers, Valuation Governance, Fees & Expenses/Allocation, Co-invest/Deal Allocation, Side Letters/MFN, Business Continuity/DR, Cybersecurity/Privacy, and Complaints/Whistleblowing.
  • Converted policies into procedures and checklists with ownership and SLAs; integrated approval workflows into existing systems (marketing review queue, personal trading/PCO tools, incident and valuation committee logs) with audit trails.
  • Authored regional variants (FCA SYSC/COBS/MAR/SMCR rules, UK AIFMD Annex IV) and documented conflict-of-law decisions where global operations required.
• Tools/frameworks used: policy/procedure library, workflow maps, checklists, RACI and SLA matrices, control narratives.
• Stakeholders involved: Compliance/Legal, IR/Marketing, Finance/Fund Accounting, Valuation Committee, IT/Cyber, HR.

Workstream 3: Annual Testing Plan and Forensic Reviews

We designed and executed a risk-based testing calendar with evidencing.

• Activities we conducted:
  • Built an annual testing plan with quarterly/annual scopes: Marketing Rule reviews (fair and balanced, testimonial and endorsement controls, hypothetical performance, substantiation), expense allocation sampling (legal, broken deal, monitoring, travel/entertainment), valuation process walkthroughs and model tie-outs, co-invest/deal allocation testing, side letter and MFN tree checks, MNPI events and wall crossing logs, personal trading pre-clearance and restricted list adherence, political contributions and pay-to-play, cyber incident tabletop and log review, BCP/DR testing, and AML/sanctions screening (where applicable).
  • Standardized workpapers, sampling, and exception classification; instituted root cause analysis and remediation tracking with due dates and accountable owners; prepared mock exam packages.
  • Presented test results in Compliance Committee and to the Board (as relevant), with trends and KRI updates; fed findings into CRA updates and policy revisions.
• Tools/frameworks used: annual testing calendar, workpaper templates, sampling plans, exception taxonomy, remediation tracker, mock exam kit.
• Stakeholders involved: CCO/testing team, Internal Audit (if present), Finance/Valuation, IR/Marketing, Deal Teams, IT/Cyber.

Workstream 4: Marketing Rule Operationalization and Recordkeeping

We minimized Marketing Rule risk while accelerating content approvals.

• Activities we conducted:
  • Centralized claims substantiation: performance calculations and backup, case studies, dispersion and PME, valuation governance narratives, and disclosures; created jurisdictional variants and deprecation rules with automated alerts.
  • Configured a marketing review workflow with SLAs, checklists (fair and balanced, hypothetical performance, testimonials/endorsements, predecessor performance), and recordkeeping (Rule 204-2) embedded; connected to CRM/IR content repositories where feasible.
  • Instituted training for content creators and approvers; monitored exceptions and trend analysis; aligned LP/consultant templates with approved definitions and disclosures.
• Tools/frameworks used: substantiation repository, disclosure templates, review workflow and checklists, deprecation calendar, exception dashboard.
• Stakeholders involved: IR/Marketing, Compliance/Legal, Data/Analytics for performance backup, Portfolio Ops for case content.

Workstream 5: Conflicts, Fees & Expenses, and Allocation Surveillance

We put measurable controls around high-scrutiny areas.

• Activities we conducted:
  • Mapped fee and expense flows; tested allocation policies (fund vs. management company vs. co-invest vehicles); reconciled expenses to LPA/side letter terms; configured exception logs and MFN tree checks for preferential terms.
  • Documented and tested deal and co-invest allocation criteria; reviewed cross/principal transactions and continuation vehicles for disclosure, fairness, and approvals; implemented exception governance for deviations.
  • Instituted quarterly forensic testing with remediation SLAs and Board/LP-ready narratives; aligned disclosures in ADV/LP reports with control design.
• Tools/frameworks used: fee/expense mapping, co-invest allocation workbook, MFN tree, exception register, disclosure crosswalk.
• Stakeholders involved: Finance/Fund Accounting, Compliance, Deal Teams, IR/Capital Formation, General Counsel.

Workstream 6: MNPI Controls, Information Barriers, and Personal Trading

We hardened MNPI governance for deal teams, Operating Partners, and board designees.

• Activities we conducted:
  • Implemented wall crossing protocols and diligence logs; refreshed restricted lists with automated alerts; enforced calendar controls for public company interactions; integrated email/meeting surveillance for MNPI keywords (proportionate to risk).
  • Upgraded personal trading (PT) system: access person designations, pre-clearance, duplicate confirms, event-driven blackout periods; retained evidence and certifications.
  • Delivered role-based MNPI training for deal teams, Operating Partners, and board designees; documented incident response and regulator notification playbooks.
• Tools/frameworks used: wall crossing log, restricted list system, PT pre-clearance tool, MNPI training curriculum, incident playbook.
• Stakeholders involved: CCO/Legal, Deal Teams, Operating Partners, HR, IT/Cyber.

Workstream 7: Cybersecurity, Privacy, BCP/DR, and Vendor Risk

We aligned operational resilience with regulatory expectations and evidencing.

• Activities we conducted:
  • Assessed and documented cybersecurity program (access controls, endpoint protection, DLP, logging/monitoring, incident response), privacy (GDPR/UK GDPR roles, DSAR workflows, data minimization), and BCP/DR (RTO/RPO definitions and tests) with evidence and testing cadence.
  • Established vendor risk oversight: due diligence questionnaires, contractual controls, periodic attestations (SOC 2/ISO), and termination rights; mapped critical vendors to BCP and cybersecurity monitoring.
  • Ran tabletop exercises and documented lessons learned; integrated results into Compliance Committee and board materials.
• Tools/frameworks used: cyber/privacy control inventory, BCP/DR test plan and results, vendor risk register and DDQ library, tabletop runbooks.
• Stakeholders involved: CISO/IT, Compliance/Legal, Operations, HR, key service providers.

Workstream 8: Regulatory Reporting and Exam Readiness

We synchronized filings and built an exam-ready posture.

• Activities we conducted:
  • Created a regulatory calendar and ownership matrix for Form ADV (annual and other-than-annual amendments), Form PF (quarterly/annual thresholds), Form D/blue sky, 13F/13H (if applicable), FCA reporting (GABRIEL/RegData, Annex IV), UK AIFMD notifications, and SMCR responsibilities and conduct rules.
  • Developed exam readiness kits: organizational charts, policy suite, testing results, exception logs, sample request lists, marketing artifacts with substantiation, fee/expense worksheets, valuation committee minutes, MNPI logs, PT reports, and BCP evidence.
  • Stood up issue management: root cause, remediation actions, testing to closure, and board/LP communication plans; tracked evolving rules (e.g., SEC private fund adviser rules, cybersecurity disclosures) with impact assessments.
• Tools/frameworks used: regulatory calendar and ownership map, exam readiness binder, horizon scanning/impact assessment log, remediation tracker.
• Stakeholders involved: Compliance/Legal, Finance, IR/Marketing, IT/Cyber, Deal Teams.

Workstream 9: Training, SMCR/Conduct Rules (where FCA), and Certifications

We embedded role-based knowledge and accountability.

• Activities we conducted:
  • Designed training curriculum by role: annual Code of Ethics, Marketing Rule, MNPI/insider trading, conflicts/fees & expenses, valuation governance, cyber/privacy and incident response, AML/sanctions (where applicable), pay-to-play; implemented SMCR conduct rules training and certifications in the UK.
  • Launched onboarding modules and quarterly micro-learnings tied to testing findings; issued certifications for high-risk workflows (marketing approvers, valuation committee members, wall crossing signatories).
  • Established training dashboards with completion, assessment scores, and exception follow-up; linked completion to system access where feasible.
• Tools/frameworks used: LMS course library and quiz bank, certification workflows, training dashboards, access gating rules.
• Stakeholders involved: Compliance, HR/L&D, IT, business unit leads.

Workstream 10: Data Architecture, Evidence, and Analytics

We enabled lineage-first compliance monitoring with measurable KRIs.

• Activities we conducted:
  • Implemented a centralized repository for policies, approvals, testing workpapers, substantiation files, and evidencing; instrumented metadata and retention policies.
  • Deployed dashboards for KRIs: marketing exceptions, expense allocation exceptions, valuation adjustments, MNPI incidents, PT violations, political contribution checks, cyber incidents, BCP tests, training completion, and remediation SLA adherence.
  • Stood up change-control for methods (performance calculations, factor sets) and disclosure glossaries; aligned with IR and board reporting to ensure one source of truth.
• Tools/frameworks used: evidence repository with RBAC, KRI dashboard suite, change-control and glossary management, data lineage documentation.
• Stakeholders involved: Compliance, Data/BI, IR/Marketing, Finance, IT.

4) Data Request

We requested datasets and artifacts required to design, operationalize, and evidence the compliance program. Typical horizons included 24–36 months of records and current policy versions.

• Corporate and organizational:
  • Org charts, role descriptions, delegation of authority matrices, SMCR responsibility maps (where FCA).
• Policy and procedure library:
  • Code of Ethics, Marketing/Communications, Books & Records, Custody, Political Contributions, Gifts & Entertainment/OBAs, MNPI/Information Barriers, Valuation Governance, Fees & Expenses/Allocation, Co-invest/Deal Allocation, Side Letters/MFN, Cybersecurity/Privacy, BCP/DR, Whistleblowing/Complaints.
• Marketing and performance:
  • Marketing materials (tear sheets, DDQs/RFPs, presentations, case studies), performance calculation workpapers, dispersion/PME, disclosures, prior exceptions; approval workflows and SLAs; substantiation files.
• Finance and valuation:
  • Expense allocations, invoices and reimbursement logs, valuation committee minutes and model documentation, fee schedules and offsets, side letter/MFN matrix, LPA/side letter extracts.
• MNPI and personal trading:
  • Wall crossing logs, restricted list records, diligence logs with public companies, personal trading system exports (pre-clearance requests, approvals, duplicate confirms), political contribution records.
• Cyber/privacy/BCP:
  • Incident logs, tabletop testing reports, vulnerability assessments, vendor risk assessments and SOC/ISO attestations, BCP/DR test results, data maps and DSAR logs.
• Regulatory filings and reporting:
  • ADV/Part 2A/2B and amendments, Form PF filings, Form D/blue sky, 13F/13H (if any), FCA RegData submissions, AIFMD Annex IV reports, SMCR certifications; prior exam requests/deficiency letters and responses.
• Training and certifications:
  • LMS records, assessment scores, Code of Ethics acknowledgments, SMCR conduct rule attestations, specialized certifications (marketing approver, valuation committee).
• Systems and data:
  • Compliance tools (PT, marketing review, incident management), data warehouse/BI schema for KRIs, RBAC/SoD mappings, evidence repository structure, retention policies.

Common data pitfalls included inconsistent policy versions and undocumented updates, marketing artifacts without substantiation, incomplete fee/expense allocation evidence, restricted list and wall crossing logs managed in spreadsheets, PT duplicate confirms missing, fragmented incident logs, and filings without ownership or retention. We established a policy register, evidence repository, and control inventory before testing and surveillance build-out.

5) Questions for Client

• What risk tolerance and supervisory expectations should drive the CRA and testing depth (e.g., focus on Marketing Rule vs. MNPI vs. fees/expenses)?
• Which policies require immediate refresh to match current practices and regulator expectations; where do exceptions recur?
• What approval SLAs are realistic for marketing review, personal trading pre-clearance, wall crossings, and valuation committee?
• How should we organize conflicts governance for co-invest/deal allocation, continuation vehicles, and side letter/MFN oversight; who should own exception adjudication?
• What surveillance tooling and data sources are available (marketing review, PT, DLP/email monitoring, incident systems); what integrations are feasible?
• What cadence and format should Compliance Committee and Board receive (KRIs, testing results, remediation log, regulatory updates)?
• Which regulatory filings and jurisdictions are in scope (SEC/FCA/AIFMD/other); what pain points exist in current workflows?
• What training and certification posture do you want by role (deal teams, IR, Operating Partners, portfolio board designees); how will completion link to access or approvals?
• What evidence retention and recordkeeping standards should we enforce (Rule 204-2, FCA/COBS), and what retention schedule applies?
• Where do you anticipate near-term regulator exams or investor ODD; what mock exam readiness is required?

6) Interview Guide for Subject Matter Experts

Chief Compliance Officer (CCO)

• Which domains have driven past deficiencies or near misses; what controls are weakest?
• How is the CRA maintained today; how are findings routed and tracked to closure?
• What reporting cadence and KRIs will you use to govern the program?

General Counsel / Legal

• Where do policies not reflect practice; what negotiation patterns in side letters and MFN raise control risks?
• How should Marketing Rule reviews and disclosures be standardized to reduce legal review bottlenecks?
• What incident and regulator engagement playbooks are needed?

CFO / Fund Controller

• Where do fee/expense allocations and valuation governance break down; what evidence is acceptable?
• How should exception governance work for allocations and cross/principal transactions?
• What cadence and format will support audit/LP transparency without adding friction?

Head of IR / Marketing

• Which content types create the most Marketing Rule risk; where do approvals stall?
• What substantiation and disclosure tools would speed responses to LP/consultant requests?

Head of Deal Teams / Operating Partner

• Where do MNPI and wall crossing risks arise; what controls are practical without slowing diligence?
• How should co-invest and deal allocations be documented to withstand testing and LP review?

CISO / Head of IT

• What cyber/privacy controls and evidencing exist; where are gaps (DLP, access logs, vendor risk)?
• What monitoring and tabletop cadence can be supported; how should incidents be integrated with compliance reporting?

Valuation Committee Chair

• How are models, assumptions, and reviews evidenced; where do conflicts with deal teams arise?
• What improvements in minutes, challenge documentation, and tie-outs would support testing?

FCA SMF Holder / UK Compliance

• What SMCR certifications and conduct rule training are required; where does UK AIFMD/Annex IV challenge workflows?
• Which FCA reporting and Principle 11 notifications require protocol updates?

Internal Audit / External ODD Advisor (if applicable)

• Which control descriptions and workpapers pass muster; what sampling and evidencing drive confidence?
• What common observations should we address preemptively?

7) Timeline

We executed a 12–14 week plan tailored to Compliance Program Design & Monitoring within Risk & Compliance.

• Weeks 1–2: Diagnostic & Governance Setup
  • Performed CRA baseline interviews and document review; built control inventory; drafted Compliance Committee charter and KRI framework; inventoried regulatory filings and marketing artifacts.
  • Decision Gate A: Approved CRA scope and priorities; confirmed governance cadence and owners.
• Weeks 3–4: Policy Refresh & Workflow Design
  • Updated policy suite; authored procedures and checklists; designed workflows for marketing review, PT pre-clearance, wall crossings, valuation minutes, fee/expense evidence; drafted regional variants (FCA/UK AIFMD).
  • Decision Gate B: Ratified policies and procedures; cleared workflow tooling and SLAs.
• Weeks 5–6: Testing Calendar & Pilot Reviews
  • Finalized annual testing plan; executed pilot forensic tests (Marketing Rule, fees/expenses, MNPI logs, PT samples); built workpaper templates and remediation registers; prepared mock exam kit structure.
  • Decision Gate C: Approved testing calendar; validated sampling and exception taxonomy.
• Weeks 7–8: Surveillance & Recordkeeping Enablement
  • Deployed marketing substantiation repository and review workflow; configured restricted list/PT tooling; set issue/exception dashboards; implemented evidence repository structure and retention.
  • Decision Gate D: Cleared surveillance go-live and recordkeeping controls; confirmed KRI dashboard design.
• Weeks 9–10: Regulatory Calendar & Exam Readiness
  • Built filing calendar and ownership; compiled exam readiness binder; executed tabletop (cyber/BCP) and documented lessons; refined disclosures/ADV/LP crosswalk.
  • Decision Gate E: Approved exam readiness and filing workflows; set remediation deadlines for open findings.
• Weeks 11–12: Training, Certifications & Handoff
  • Delivered role-based training and SMCR (where applicable); launched certifications; finalized KRI dashboards and board report template; transferred runbooks and change-control processes.
  • Decision Gate F: Authorized steady-state operations; scheduled quarterly CRA and testing updates.
• Weeks 13–14 (optional): Mock Exam & Optimization
  • Conducted mock SEC/FCA exam; tuned sampling and workflows; optimized approval SLAs; prioritized automation and integration opportunities.

Critical path items included agreement on CRA priorities, policy-to-procedure conversion, surveillance tooling and evidence repository deployment, testing plan ratification, regulatory calendar ownership, and role-based training with certifications.

8) Deliverables

• Compliance Risk Assessment & Control Inventory
  • Heat map of inherent/residual risks; control inventory with owners, frequency, evidence, and testing steps; KRI framework and dashboards.
• Policy & Procedure Suite (SEC/FCA-ready)
  • Refreshed policies (Code of Ethics, Marketing Rule, MNPI, Valuation, Fees & Expenses, Allocation, Side Letters/MFN, Custody, Pay-to-Play, Cyber/Privacy, BCP/DR) with procedures, checklists, and regional variants.
• Annual Testing Plan & Workpaper Library
  • Risk-based testing calendar; sampling plans; workpaper templates; exception taxonomy; remediation tracker; board/Compliance Committee reporting pack.
• Marketing Rule Operationalization Pack
  • Substantiation repository, disclosure templates, review workflow/checklists, deprecation calendar, recordkeeping scripts (Rule 204-2).
• Conflicts & Allocation Surveillance Toolkit
  • Fee/expense mapping and sampling, co-invest/deal allocation workbook, MFN tree and exception log, cross/principal transaction review guide.
• MNPI & Personal Trading Controls
  • Wall crossing and diligence logs, restricted list governance, PT pre-clearance workflow and evidence forms, incident playbook.
• Cyber/Privacy/BCP Evidence & Test Packs
  • Control narratives, test plans and results, vendor risk register and DDQs, tabletop scripts and after-action reports, BCP/DR documentation.
• Regulatory Calendar & Exam Readiness Binder
  • Filing calendar/ownership, document index, prior deficiency responses, sample request responses, mock exam runbook.
• Training Curriculum & Certifications
  • Role-based modules, SMCR conduct rules (where applicable), assessments, certification workflows, training dashboards.
• Evidence Repository & KRI Dashboards
  • Lineage-first evidence library with RBAC/retention; dashboards for marketing exceptions, allocation/valuation exceptions, MNPI/PT, cyber/BCP, training, remediation SLAs.

9) Industry Insights

• Marketing Rule enforcement is a top exam theme
  • Substantiation, fair and balanced presentation, and hypothetical performance controls are central; centralized evidence and approval workflows reduce exceptions and speed IR responses.
• Fees, expenses, and preferential treatment remain high-risk
  • Expense allocation, co-invest and deal allocation, continuation vehicles, and side letter/MFN oversight draw scrutiny; forensic testing and MFN trees are becoming expected by sophisticated LPs.
• MNPI and board seat risks are rising in PE
  • Wall crossing discipline, restricted lists, and PT controls must match increased public-to-private activity and Operating Partner board roles; email/calendar surveillance and diligence logs help evidence control effectiveness.
• Cyber/privacy and BCP evidencing matters as much as policy
  • Tabletop results, vendor oversight, access logs, and incident runbooks are frequently requested in exams and ODD; documentation and retention drive credibility.
• SEC and FCA expect living programs
  • Risk assessments, testing calendars, and remediation logs should be updated as products and geographies evolve; static policies without operational proof invite deficiencies.
• Recordkeeping is the quiet failure point
  • Rule 204-2 and FCA record rules require structured repositories and retention; ad hoc storage undermines Marketing Rule and allocation evidencing.
• What “good” looks like
  • A risk-based CRA, refreshed policy suite, testing calendar with workpapers, operationalized Marketing Rule controls, conflicts/allocation surveillance, hardened MNPI/PT, cyber/privacy and BCP evidencing, regulatory calendar and exam kit, role-based training, and KRI dashboards—governed by a Compliance Committee with remediation SLAs.
• Near-term watch points
  • Marketing Rule examinations, evolving SEC private fund adviser rules and litigation outcomes, cybersecurity disclosure expectations, FCA SMCR accountability, UK AIFMD/Annex IV changes, greenwashing enforcement, and data privacy regime updates. Quarterly CRA and testing refresh sustain readiness and reduce deficiency risk.

Implications for clients we served included enabling Mega/Large-Cap Private Equity Buyout Firms to evidence robust controls across complex, multi-jurisdiction operations; supporting Mid-Market & Lower Mid-Market Private Equity Sponsors to institutionalize a pragmatic, exam-ready program quickly; equipping Growth Equity Investors (Private Equity) to manage Marketing Rule and MNPI risk with lean teams; guiding Private Equity Operating Partners & Value Creation Teams to operate within information barriers while delivering value; and providing PE-Owned Portfolio Companies clarity on board seat protocols, data privacy/cyber practices, and evidence standards that support sponsor compliance and investor trust.